Therapy for Genitourinary Cancer

Inbunden, Engelska, 1992

AvHerbert Lepor,Russell K. Lawson,Russell K Lawson

2 079 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

In this volume, the roles of adjuvant radiotherapy following radical prostatectomy and complete androgen suppression for metastatic prostate cnacer are reviewed, as well as the preliminary experiences with suramin and the implications of combining tumour necrosis factor and chemotherapeutic drugs. The use of bladder substitution with intestinal segments has enhanced the quality of life following pelvic exerterative surgery; the development of carcinoma in these intestinal bladders is discussed. "Therapy for Genitourinary Cancer" reflects the commitment of clinicians and basic scientists to enhance the effectiveness of therapy for genitourinary malignancies. It is hoped that the innovative approaches to treatment presented in this volume will gain clinical acceptance and improve the ability to cure these tumours.

Produktinformation

Utgivningsdatum1992-03-31
Mått155 x 235 x 11 mm
Vikt426 g
FormatInbunden
SpråkEngelska
SerieCancer Treatment and Research
Antal sidor159
Upplaga1992
FörlagKluwer Academic Publishers
ISBN9780792314127

Tillhör följande kategorier

Onkologi inom Medicin

1. Genitourinary rhabdomyosarcoma in childhood: Current treatment alternatives and controversies in management.- 2. Renal-sparing surgery for renal and transitional cell carcinoma.- 3. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade.- 4. The role of radiotherapy following radical prostatectomy.- 5. Nuclear DNA ploidy and prostate cancer.- 6. Brachytherapy of localized penile carcinoma.- 7. Malignancy associated with urinary tract reconstruction using enteric segments.- 8. Evolving concepts in surgical management of testis cancer.- 9. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.- 10. Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies.- 11. Cell motility as an index of metastatic ability in prostate cancers: Results with an animal model and with human cancer cells.- 12. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors.